Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol - Takeaways - MDSpire

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • By

  • Rami El Shafie

  • Jonas Willmann

  • Eleni Gkika

  • Tanja Schimek-Jasch

  • Matthias Miederer

  • Farastuk Bozorgmehr

  • Frank Griesinger

  • Farkhad Manapov

  • Petros Christopoulos

  • Thomas Hehr

  • Markus Hecht

  • Rebecca Bütof

  • Martin Stuschke

  • Matthias Guckenberger

  • Gerald Schmid-Bindert

  • Jan Meiners

  • Sascha Herzer

  • Sonja Hartmann

  • Joana Lamché

  • Stefan Rieken

  • Ursula Nestle

  • April 17, 2026

  • 0 min

Share

  • 1

    Lung cancer is a leading cause of cancer deaths globally, with non-small cell lung cancer (NSCLC) accounting for 80-90% of cases.

  • 2

    The standard treatment for unresectable stage III NSCLC includes concurrent chemoradiation followed by consolidation immunotherapy with durvalumab.

  • 3

    Integration of FDG-PET/CT enhances radiotherapy planning by accurately defining tumor volumes, potentially improving local control and reducing toxicity.

  • 4

    Hypofractionated radiotherapy schedules may offer comparable or lower toxicity rates while accelerating treatment duration for stage III NSCLC.

  • 5

    Biomarkers like neutrophil-lymphocyte ratio and advanced lung cancer inflammation index could predict treatment response and survival in NSCLC patients.

Original Source(s)

Accelerated Immuno Chemoradiotherapy Based on FDG-PET/CT for Small Volume in Locally Advanced NSCLC (PACCELIO) – A Phase II Multicenter Randomized Open-Label Trial Protocol

  • by Rami El Shafie, Jonas Willmann, Eleni Gkika, Tanja Schimek-Jasch, Matthias Miederer, Farastuk Bozorgmehr, Frank Griesinger, Farkhad Manapov, Petros Christopoulos, Thomas Hehr, Markus Hecht, Rebecca Bütof, Martin Stuschke, Matthias Guckenberger, Gerald Schmid-Bindert, Jan Meiners, Sascha Herzer, Sonja Hartmann, Joana Lamché, Stefan Rieken, Ursula Nestle

  • April 17, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?